• Alias: PD0332991
    • A reversible small-molecule CDK inhibitor that is selective for CDK 4 and 6. CDKs have a role in regulating progression through the cell cycle at the G1/S phase by blocking retinoblastoma (Rb) hyperphosphorylation. It reduces the proliferation of breast cancer cell lines by preventing progression from the G1 to the S cell cycle phase.
    • FDA approved with hormone therapy for hormone receptor–positive, HER2-negative breast cancer or advanced breast cancer with disease progression on hormone therapy.
    • Recommended dose: 125 mg PO daily for 21 days of the 28-day cycle. No rapefruit juice
    Other topics in Targeted and Immunotherapy Agents